Should I Take Semaglutide? How a Provider Decides

Semaglutide can be worth discussing when weight is affecting health, but meeting a weight threshold doesn't settle the decision. Our fictional composite reader is 44, has a BMI of 32—body mass index, a weight-to-height measure—and has tried two structured diet programs. They take blood-pressure medication, and a recent lab showed prediabetes: blood sugar above the usual range but below the diabetes threshold.

If you're asking “should I take semaglutide?”, here is how a provider works through that picture, one question at a time.

1. Should I take semaglutide if I meet the weight criteria?

A BMI of 32 puts this reader within the adult weight-management population described in the Wegovy label. The familiar thresholds are 30 or higher, or 27 or higher with a weight-related condition, such as high blood pressure. The NIDDK's prescribing overview explains why health history and previous weight-management efforts matter too.

As of September 10, 2026, the day this article was written, the Wegovy prescribing information on DailyMed carries “Revised: 6/2026.” Its weight-management use includes food and activity changes alongside medication.

Prediabetes gives the discussion another reason. In STEP 10, a 207-person trial published in The Lancet Diabetes & Endocrinology in 2024, about 4 in 5 semaglutide participants with measurements at week 52 met the study's normal-blood-sugar definition: 81%, versus 14% with placebo, a treatment without active medicine. Both groups received lifestyle counselling. Those findings don't predict this reader's result or establish permanent diabetes prevention. Eligibility starts the review; the provider decides.

2. Who should not take semaglutide because of thyroid history?

Wegovy and Ozempic, another semaglutide brand, both rule out use with a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer, or MEN 2, an inherited condition that raises its risk. Their boxed warning—the most prominent label warning—comes from thyroid tumors in mice and rats; the relevance to humans remains unknown.

A previous serious allergic reaction to semaglutide also matters. These are contraindications, meaning reasons the medicine should not be used. If the family history is unclear, the diagnosis needs clarifying before proceeding; the provider decides.

3. Has there been pancreatitis?

Pancreatitis means inflammation of the pancreas, an organ involved in digestion and blood-sugar control. Both labels warn that cases have occurred. A past episode isn't listed as a formal contraindication, but its cause, timing and recurrence matter.

For our reader, the next step may be getting an old hospital record. “Stomach trouble years ago” isn't enough detail to judge that risk; the provider decides.

4. What about gallstones or gallbladder disease?

Gallstones are hardened deposits in the gallbladder, the small organ that stores digestive fluid. Previous inflammation or surgery, and current symptoms, matter here. In STEP 1, a 1,961-person trial published in the New England Journal of Medicine in 2021, gallbladder-related disorders occurred in 2.6% with semaglutide and 1.2% with placebo. The paper reported mostly gallstones.

That history needs its own answer even if the pancreas history is clear. Depending on the details, the review may need further assessment; the provider decides.

5. Is there diabetic eye disease?

Diabetic retinopathy is damage to the light-sensitive tissue at the back of the eye. A 2018 analysis in Diabetes, Obesity and Metabolism linked much of the eye-complication signal in the SUSTAIN 6 trial to rapid blood-sugar improvement in people with existing eye disease, poorly controlled diabetes and insulin use.

Our reader has prediabetes, so those findings don't directly describe them. Previous eye damage deserves particular attention, but complications weren't confined to people with known damage. Eye history and any new vision symptoms shape the review; the provider decides.

6. How do the kidneys and blood-pressure medicine fit?

Vomiting or diarrhea can cause dehydration—too little fluid in the body—and strain the kidneys. The Wegovy label also reports low blood pressure more often among people taking blood-pressure medicine.

Our reader's medication name, usual readings and recent kidney results therefore matter together. The provider may coordinate monitoring with the clinician managing their pressure. If tirzepatide comes up as an alternative, tirzepatide and blood pressure explains why it needs a similar conversation. A different medicine still needs an individual review; the provider decides.

7. Could pregnancy be part of the near-term plans?

For weight management, the Wegovy label directs discontinuation when pregnancy is recognized and at least 2 months before a planned pregnancy. Semaglutide leaves the body slowly.

The reader's age doesn't answer this question. Pregnancy plans could change whether treatment starts now, and any transition needs a care plan; the provider decides.

8. What has eating felt like during those diet programs?

Two previous programs tell us very little about this reader's relationship with food. The review includes eating-disorder history, severe restriction, binge eating and distress around meals.

As of September 10, 2026, the day this article was written, a consensus statement shared by the European Association for the Study of Obesity on July 9, 2026 calls for nutrition care, psychological support and attention to disordered eating alongside these medicines. For this reader, that may mean specialist input before any prescription; the provider decides.

9. Are other weight or diabetes medicines involved?

GLP-1 medicines act on a hormone signal involved in appetite and blood sugar. Wegovy's label does not recommend combining it with another semaglutide product or another GLP-1 medicine. Insulin, a blood-sugar-lowering medicine, raises the low-blood-sugar risk when combined with semaglutide.

The full list matters, including anything prescribed elsewhere. Semaglutide drug interactions covers that review, and questions to bring about tirzepatide covers the alternative's intake. Any change or transition needs a coordinated plan; the provider decides.

10. Is there a workable plan for side effects and follow-up?

In STEP 1, about 1 in 22 semaglutide participants stopped because of stomach or bowel effects: 4.5%, versus 0.8% with placebo. The trial report described nausea and diarrhea as usually temporary and mild to moderate.

For our reader, the practical questions are who responds to symptoms, how follow-up fits daily life, and whether ongoing care is affordable. The prescriber sets the actual dose. Willingness to endure symptoms isn't a qualification test; the provider decides.

11. What does a “no” look like?

It may mean the medicine doesn't fit, more information is needed, or another condition needs attention first. A provider's ability to decline is part of the care. What to expect from the first visit explains the process.

Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means preparing a medicine for an individual prescription. FDA explains the distinction. The trials above did not test Promise's formulation.

A licensed provider may still prescribe a compounded formulation when appropriate under applicable rules; that decision is between the patient and the doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. Our reader's review ends with a reasoned recommendation, not a promised prescription; the provider decides.